References
- American Diabetes Association Diabetes Statistics Available from http://www.diabetes.org/diabetes-basics/diabetes-statistics/ Accessed September 14, 2013
- Mitka M More patients get good diabetes control, but only a minority meet all goals JAMA 2013 309 13 1335 1336 23549561
- Inzucchi SE Bergenstal RM Buse JB position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach Diabetes Care 2012 35 10 1364 1379 22517736
- Chao EC Henry RR SGLT2 Inhibition – a novel strategy for diabetes treatment Nat Rev Drug Discov 2010 9 7 551 559 20508640
- Wright EM Renal Na+ glucose cotransporters Am J Physiol Renal Physiol 2001 280 1 F10 F18 11133510
- Mackenzie B Loo DD Panayotova-Heiermann M Wright EM Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2 J Biol Chem 1996 271 51 32678 32683 8955098
- Kanai Y Lee WS You G Brown D Hediger MA The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose J Clin Invest 1994 93 1 397 404 8282810
- Farber SJ Berger EY Earle DP Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose J Clin Invest 1951 30 2 125 129 14814204
- Sha S Devineni D Ghosh A Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 2011 13 669 672 21457428
- Polidori D Sha S Mudaliar S Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study Diabetes Care 2013 36 8 2154 2161 23412078
- INVOKANA® (canagliflozin) [package insert] Titusville, NJ Janssen Pharmaceuticals, Inc 2013
- Stenlöf K Cefalu WT Kim KA Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 2013 15 4 372 382 23279307
- Rosenstock J Aggarwal N Polidori D Canagliflozin DIA 2001 Study Group Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 2012 35 6 1232 1238 22492586
- Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea Diabetes Care 2013 36 9 2508 2515 23564919
- Devineni D Morrow L Hompesch M Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes Obes Metab 2012 14 6 539 545 22226086
- Yale JF Bakris G Cariou B Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 2013 15 5 463 473 23464594
- Bode B Stenlöf K Sullivan D Fung A Usiskin K Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract 2013 41 2 72 84
- GoodRx [webpage on the Internet] Available from: http://www.goodRx.com Accessed September 15, 2013
- Neal B Perkovic V de Zeeue D Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS) – a randomized placebo controlled trial Am Heart J 2013 166 2 217 223 23895803
- Zambrowicz B Freiman J Brown PM LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial Clin Pharmacol Ther 2012 92 2 158 169 22739142